A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Clinical trial NCT07229729 · RECRUITING
Trial details
- NCT number
- NCT07229729
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-24
- Primary completion
- 2026-10-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.